{"entity":{"id":"paper-checkmate-577-nejm-2021","kind":"paper","name":"CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer","aka":[],"tldr":"A year of nivolumab after chemoradiotherapy and surgery doubled disease-free survival in patients with oesophageal or junctional cancer who still had residual tumour at surgery, the first adjuvant therapy to work in this setting.","summary":"Phase 3 placebo-controlled trial of 794 patients with resected stage II to III oesophageal or gastro-oesophageal junction cancer (both histologies) and residual pathological disease after neoadjuvant chemoradiotherapy, randomised 2:1 to nivolumab or placebo for up to one year.\n\nMedian disease-free survival was 22.4 versus 11.0 months (hazard ratio 0.69), with benefit in both squamous and adenocarcinoma and regardless of PD-L1 expression; grade 3 to 4 treatment-related adverse events were 13 versus 6 percent.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2021","url":"https://doi.org/10.1056/NEJMoa2032125"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33789008/"}],"tags":[],"related":[],"cancers":["oesophageal-squamous-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-577"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2021,"doi":"10.1056/NEJMoa2032125","pmid":"33789008","authors":"Kelly RJ, Ajani JA, Kuzdzal J, et al.","paperType":"rct","findings":["Median disease-free survival 22.4 vs 11.0 months; hazard ratio 0.69.","Benefit in squamous (hazard ratio 0.61) and adenocarcinoma (0.75)."],"whatItMeans":"Adjuvant nivolumab is standard for patients with residual disease after trimodality therapy for oesophageal cancer.","caveats":["Overall survival data pending.","Applies only after neoadjuvant chemoradiotherapy, not after perioperative chemotherapy."],"changedPractice":true,"participants":794},"route":"/key-papers/paper-checkmate-577-nejm-2021/","neighbours":{"cancer":[{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}